Holen Sie sich die Stockscreener-App
1,040.00
0.17%
1.73
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$1,038.27
Offen:
$1039.98
24-Stunden-Volumen:
2.70M
Relative Volume:
0.79
Marktkapitalisierung:
$930.82B
Einnahmen:
$65.18B
Nettoeinkommen (Verlust:
$20.64B
KGV:
45.31
EPS:
22.9554
Netto-Cashflow:
$6.44B
1W Leistung:
-1.72%
1M Leistung:
-3.45%
6M Leistung:
+57.46%
1J Leistung:
+19.29%
1-Tages-Spanne:
$1,033.69
$1,064.34
1-Wochen-Bereich:
$1,012.00
$1,106.94
52-Wochen-Spanne:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,040.00 | 929.27B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
243.45 | 589.19B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
231.50 | 402.08B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
205.55 | 317.06B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
163.10 | 307.56B | 54.72B | 14.02B | 15.32B | 7.1855 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-16 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Bestätigt | BofA Securities | Buy |
| 2025-12-15 | Bestätigt | Goldman | Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-10 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Bestätigt | BMO Capital Markets | Outperform |
| 2025-10-14 | Hochstufung | Erste Group | Hold → Buy |
| 2025-09-17 | Herabstufung | Berenberg | Buy → Hold |
| 2025-08-27 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Herabstufung | Erste Group | Buy → Hold |
| 2025-04-28 | Herabstufung | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
International Private Wealth Advisors LLC Purchases 1,366 Shares of Eli Lilly and Company $LLY - MarketBeat
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Eli Lilly (LLY) Prepares Orforglipron Inventory Ahead of FDA Dec - GuruFocus
Did Eli Lilly Just Make a Deal for Its Next Blockbuster Drug? - The Motley Fool
Eli Lilly (LLY) Retains Buy Rating on Strong 2026 Outlook - Insider Monkey
Eli Lilly and Company (LLY) Gets Upgraded to Buy From Hold by Freedom Capital - Finviz
Eli Lilly and Company (NYSE:LLY) Stock Price Expected to Rise, CICC Research Analyst Says - MarketBeat
Eli Lilly builds $1.5 billion stockpile of weight-loss pill ahead of FDA decision - Reuters
Rx Rundown: Eli Lilly, Supreme Group, Regenxbio and more - Medical Marketing and Media
Eli Lilly boosts weight loss pill inventory ahead of FDA decision - Seeking Alpha
Eli Lilly and Company $LLY Shares Bought by Public Sector Pension Investment Board - MarketBeat
Eli Lilly Builds $1.5 Billion Inventory Of Experimental Weight-Loss Pill As FDA Decision Looms - Benzinga
City Council approves $6 billion Eli Lilly plant, addresses recycling issues - WAFF
Lilly Stock Upgraded to Strong Buy as Growth Momentum and RNA Therapeutics Bet Take Center Stage - AD HOC NEWS
Eli Lilly Uses GLP 1 Cash Flows To Pursue Next Wave RNA Therapies - simplywall.st
ELI LILLY & Co SEC 10-K Report - TradingView
Eli Lilly Stock (LLY) Gets New ‘Buy Rating’ After Strong Earnings - TipRanks
Lilly’s $2.4B bet on off-the-shelf cell therapy is part of a wider Big Pharma shift - PharmaVoice
Eli Lilly and Company $LLY Stock Position Increased by Varma Mutual Pension Insurance Co - MarketBeat
How to Play Eli Lilly Stock Following a Robust Q4 Earnings Report - Nasdaq
Savvy Advisors Inc. Has $7.36 Million Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2026-2030 (Jan 2026) - 24/7 Wall St.
Eli Lilly and Company (NYSE:LLY) Stock Rating Upgraded by Freedom Capital - MarketBeat
Eli Lilly Extends Lead in Weight-Loss Drug Market - AD HOC NEWS
Fund Update: 382,112 ELI LILLY (LLY) shares added to PARNASSUS INVESTMENTS, LLC portfolio - Quiver Quantitative
Illinois Municipal Retirement Fund Sells 1,002 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. - Yahoo Finance
Atria Investments Inc Has $30.79 Million Stake in Eli Lilly and Company $LLY - MarketBeat
Is Eli Lilly and Company (NYSE:LLY) Strengthening its Position In S&P 500 Futures - Kalkine Media
Eli Lilly Leadership Receives Stock Awards Amid Strong Growth Forecast - AD HOC NEWS
Eli Lilly and Company (LLY) to Acquire Orna Therapeutics in $2.4B Deal to Expand RNA Pipeline - Insider Monkey
7th Circ. Mulls Expiration Date Of Teva, Eli Lilly Patent Deal - Law360
Novo to Follow Lilly and Sell Obesity Shot Wegovy in Vials - Bloomberg
Top Analyst Reports for Eli Lilly, Marriott & Fortinet - TradingView
Robust Demand for Eli Lilly and Company (LLY)'s Obesity and Diabetes Treatments Drives Strong Investor Sentiment - Finviz
Robust Demand for Eli Lilly and Company (LLY)’s Obesity and Diabetes Treatments Drives Strong Investor Sentiment - Yahoo Finance
3 Reasons to Buy Eli Lilly Stock - Yahoo Finance
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly - Stocktwits
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. - AOL.com
Ex-Dividend Reminder: Bio-Techne, 3M and Eli Lilly - Nasdaq
Eli Lilly and Company $LLY Shares Bought by Westbourne Investments Inc. - MarketBeat
Krilogy Financial LLC Acquires Shares of 4,276 Eli Lilly and Company $LLY - MarketBeat
Mechanics Financial Corp Has $1.98 Million Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Sold by Rhumbline Advisers - MarketBeat
Eli Lilly and Company $LLY Stock Position Raised by Madison Asset Management LLC - MarketBeat
Stratos Wealth Partners LTD. Grows Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company $LLY Shares Acquired by Jensen Investment Management Inc. - MarketBeat
The Top 5 Analyst Questions From Eli Lilly's Q4 Earnings Call - Finviz
CICC Adjusts Price Target on Eli Lilly and Co. to $1,107 From $1,060, Maintains Neutral Rating - marketscreener.com
Cibc World Market Inc. Buys 49,634 Shares of Eli Lilly and Company $LLY - MarketBeat
61,694 Shares in Eli Lilly and Company $LLY Acquired by Caprock Group LLC - MarketBeat
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):